Management & Regulatory

The rapid expansion of semaglutide from a targeted glycemic control agent to a global phenomenon for weight management has now set the stage for an even more profound shift into the realm of addiction medicine. While the drug, marketed under various brand names, has already fundamentally altered

The recent decision by the Yass Valley Council to grant official approval for a comprehensive medical imaging facility marks a pivotal moment in the modernization of regional healthcare infrastructure and patient accessibility. This Development Application, finalized under the Yass Valley

Signals from a pivotal trial now cut through the noise of a crowded obesity market, forcing hard questions about where dual agonists belong and how quickly they can reshape care. Obesity has shifted from a lifestyle narrative to a biologic disease with organ-level consequences, most notably in the

Chloe Botaine sat down with Ivan Kairatov, a Biopharma expert with deep R&D and tech experience, to discuss the European Commission’s approval of a long-acting monoclonal antibody for RSV prevention in newborns and infants. With a single intramuscular dose designed to protect for up to five months,

Swift regulatory action upended a fragile corner of San Antonio’s behavioral health system when federal officials moved to terminate Medicare and Medicaid participation for a major psychiatric hospital that treats children, adolescents, adults, veterans, and people with substance use disorders,

Matthias Aizenberg sits down with Ivan Kairatov, a biopharma expert whose work straddles gene editing and viral delivery, to unpack a new way of building better gene-editing vehicles by rethinking the cells that make them. Rather than only re-engineering virus-like particles, his team interrogated